Search Results - "Gilks, C."

Key changes to the World Health Organization (WHO) classification of female genital tumours introduced in the 5th edition (2020) by McCluggage, W Glenn, Singh, Naveena, Gilks, C Blake

“…An updated World Health Organization (WHO) classification of female genital tumours was published in autumn 2020. We discuss the major new additions to and…”
Get full text

Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists by Soslow, Robert A, Tornos, Carmen, Park, Kay J, Malpica, Anais, Matias-Guiu, Xavier, Oliva, Esther, Parkash, Vinita, Carlson, Joseph, McCluggage, W Glenn, Gilks, C Blake

“…In this review, we sought to address 2 important issues in the diagnosis of endometrial carcinomahow to grade endometrial endometrioid carcinomas and how to…”
Get full text

Vulval squamous cell carcinoma and its precursors by Singh, Naveena, Gilks, C Blake

“…Vulval squamous cell carcinoma (VSCC) can arise through two distinct pathways [human papillomavirus (HPV)‐associated and HPV‐independent], and these VSCC…”
Get full text

Dr. Naveena Singh, Dec 7 1964 - Oct 5 2023 by Ganesan, Raji, Blake Gilks, C

Get full text

Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer by Talhouk, Aline, McConechy, Melissa K., Leung, Samuel, Yang, Winnie, Lum, Amy, Senz, Janine, Boyd, Niki, Pike, Judith, Anglesio, Michael, Kwon, Janice S., Karnezis, Anthony N., Huntsman, David G., Gilks, C. Blake, McAlpine, Jessica N.

“…BACKGROUND Classification of endometrial carcinomas (ECs) by morphologic features is irreproducible and imperfectly reflects tumor biology. The authors…”
Get full text

Endometrial carcinoma: molecular subtypes, precursors and the role of pathology in early diagnosis by Huvila, Jutta, Pors, Jennifer, Thompson, Emily F, Gilks, C Blake

“…Endometrial carcinoma (EC) is classified into a wide range of morphological variants; this list has expanded over the past decade with the inclusion of…”
Get full text

Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma by Talhouk, Aline, Derocher, Heather, Schmidt, Pascal, Leung, Samuel, Milne, Katy, Gilks, C Blake, Anglesio, Michael S, Nelson, Brad H, McAlpine, Jessica N

“…Tumors with high mutation load are thought to engender stronger immune responses, which in turn promote prolonged patient survival. To investigate this, we…”
Get full text

Interpretation of somatic POLE mutations in endometrial carcinoma by León‐Castillo, Alicia, Britton, Heidi, McConechy, Melissa K, McAlpine, Jessica N, Nout, Remi, Kommoss, Stefan, Brucker, Sara Y, Carlson, Joseph W, Epstein, Elisabeth, Rau, Tilman T, Bosse, Tjalling, Church, David N, Gilks, C Blake

“…Pathogenic somatic missense mutations within the DNA polymerase epsilon (POLE) exonuclease domain define the important subtype of ultramutated tumours…”
Get full text

Clinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas by León‐Castillo, Alicia, Gilvazquez, Ester, Nout, Remi, Smit, Vincent THBM, McAlpine, Jessica N, McConechy, Melissa, Kommoss, Stefan, Brucker, Sara Y, Carlson, Joseph W, Epstein, Elisabeth, Rau, Tilman T, Soslow, Robert A, Ganesan, Raji, Matias‐Guiu, Xavier, Oliva, Esther, Harrison, Beth T, Church, David N, Gilks, C Blake, Bosse, Tjalling

“…Endometrial carcinoma (EC) molecular classification based on four molecular subclasses identified in The Cancer Genome Atlas (TCGA) has gained relevance in…”
Get full text

Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma by Gilks, C Blake, Oliva, Esther, Soslow, Robert A

“…Patients with high-grade subtypes of endometrial carcinoma (grade 3 endometrioid, serous, clear cell, or carcinosarcoma) have a relatively poor prognosis. The…”
Get full text

Ovarian carcinoma pathology and genetics: recent advances by Gilks, C. Blake, MD, Prat, Jaime, MD

“…Summary In this review we summarize recent advances in the histopathological diagnostic criteria and molecular pathology of the main subtypes of ovarian…”
Get full text

p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification by Jamieson, Amy, Thompson, Emily F, Huvila, Jutta, Gilks, C Blake, McAlpine, Jessica N

“…Over the past decade, our understanding of endometrial cancer has changed dramatically from the two-tiered clinicopathologic classification system of type I…”
Get more information

p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies by Singh, Naveena, Piskorz, Anna M, Bosse, Tjalling, Jimenez‐Linan, Mercedes, Rous, Brian, Brenton, James D, Gilks, C Blake, Köbel, Martin

“…TP53 mutations are considered a surrogate biomarker of the serous‐like ‘copy number high’ molecular subtype of endometrial carcinoma (EC). In ovarian…”
Get full text

L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile by Kommoss, Felix KF, Karnezis, Anthony N., Kommoss, Friedrich, Talhouk, Aline, Taran, Florin-Andrei, Staebler, Annette, Gilks, C. Blake, Huntsman, David G., Krämer, Bernhard, Brucker, Sara Y., McAlpine, Jessica N., Kommoss, Stefan

“…Background The newly developed Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) has consistently been shown to be prognostically…”
Get full text

Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes by Asleh, Karama, Negri, Gian Luca, Spencer Miko, Sandra E., Colborne, Shane, Hughes, Christopher S., Wang, Xiu Q., Gao, Dongxia, Gilks, C. Blake, Chia, Stephen K. L., Nielsen, Torsten O., Morin, Gregg B.

“…Despite advances in genomic classification of breast cancer, current clinical tests and treatment decisions are commonly based on protein level information…”
Get full text

Rare cancers: a sea of opportunity by Boyd, Niki, PhD, Dancey, Janet E, Prof, Gilks, C Blake, Prof, Huntsman, David G, Prof

“…Summary Rare cancers, as a collective, account for around a quarter of all cancer diagnoses and deaths. Historically, they have been divided into two groups:…”
Get full text

The disparate origins of ovarian cancers: pathogenesis and prevention strategies by Karnezis, Anthony N., Cho, Kathleen R., Gilks, C. Blake, Pearce, Celeste Leigh, Huntsman, David G.

“…Ovarian cancer comprises a broad range of histologically and genetically different tumours. In this Opinion article, Karnezis et al . explore the different…”
Get full text

Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status by Tessier-Cloutier, Basile, Kortekaas, Kim E., Thompson, Emily, Pors, Jennifer, Chen, Julia, Ho, Julie, Prentice, Leah M., McConechy, Melissa K., Chow, Christine, Proctor, Lily, McAlpine, Jessica N., Huntsman, David G., Gilks, C. Blake, Bosse, Tjalling, Hoang, Lynn N.

“…The recent literature has shown that vulvar squamous cell carcinoma (VSCC) can be stratified into two prognostically relevant groups based on human…”
Get full text

Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility by Köbel, Martin, Ronnett, Brigitte M, Singh, Naveena, Soslow, Robert A, Gilks, C Blake, McCluggage, W Glenn

“…P53 immunohistochemistry has evolved into an accurate surrogate reflecting the underlying TP53 mutation status of a tumor, and has utility in the diagnostic…”
Get full text

The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future by Goebel, Emily A., Vidal, August, Matias-Guiu, Xavier, Blake Gilks, C.

“…Uterine cancer was first subclassified based on anatomic site, separating those tumours arising from the endometrium from cervical cancers. There was then…”
Get full text